29,923 Shares in Haemonetics Corporation $HAE Bought by Horizon Investments LLC

Key Points

• Horizon Investments LLC opened a new position of 29,923 Haemonetics shares in Q4, valued at about $2.398 million and representing roughly 0.06% of the company.
• Recent results: Haemonetics reported $1.31 EPS (beating by $0.04) and $338.97M revenue for the quarter, set FY2026 guidance of 4.900–5.000 EPS, and analysts forecast about 4.95 EPS for the year.
• Institutional and analyst picture: Institutional investors hold 99.67% of the stock with active position changes (e.g., UBS increased to 156,138 shares worth $9.923M); the consensus rating is a "Moderate Buy" with an average target of $82.78 amid some recent target cuts.

Horizon Investments LLC bought a new position in shares of Haemonetics Corporation (NYSE:HAE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,923 shares of the medical instruments supplier's stock, valued at approximately $2,398,000. Horizon Investments LLC owned about 0.06% of Haemonetics at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Haemonetics by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of Haemonetics during the first quarter worth $216,000. United Services Automobile Association purchased a new position in shares of Haemonetics during the first quarter worth $212,000. Empowered Funds LLC raised its holdings in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock worth $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock worth $9,923,000 after purchasing an additional 9,051 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

HAE opened at $55.64 on Wednesday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The firm has a fifty day moving average price of $59.85 and a 200 day moving average price of $66.63. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The stock has a market cap of $2.59 billion, a P/E ratio of 15.33, a P/E/G ratio of 1.08 and a beta of 0.53.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The firm had revenue of $338.97 million during the quarter, compared to analysts' expectations of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business's revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities research analysts anticipate that Haemonetics Corporation will post 4.95 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on HAE shares. Wall Street Zen raised shares of Haemonetics from a "hold" rating to a "buy" rating in a report on Saturday, January 10th. Mizuho decreased their target price on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating for the company in a research note on Monday, April 13th. Citigroup decreased their target price on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating for the company in a research note on Wednesday, March 11th. BTIG Research reiterated a "buy" rating and issued a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Finally, Robert W. Baird set a $81.00 target price on shares of Haemonetics in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Haemonetics presently has a consensus rating of "Moderate Buy" and an average target price of $82.78.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.